GPCR تصريحات هيئة الأوراق المالية والبورصات - Structure Therapeutics Inc. - Depositary Receipt (Common Stock)- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1888886

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Structure Therapeutics Inc. - Depositary Receipt (Common Stock)

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Structure Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (
August 6, 2025	EX-4.7	Form of Preferred Share Warrant Agreement and Warrant Certificate.   Exhibit 4.7   Structure Therapeutics Inc.   and   , As Warrant Agent   Form of Preferred Shares Warrant Agreement   Dated As Of       Structure Therapeutics Inc. Form of Preferred Shares Warrant Agreement   This Preferred Shares Warrant Agreement (this “Agreement”), dated as of [●], between Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Stru
August 6, 2025	EX-99.1	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinica Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small molecule amylin receptor agonist (ACCG-
August 6, 2025	EX-4.10	Form of Indenture, between Registrant and One or More Trustees to be Named. Exhibit 4.10 Structure Therapeutics Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate
August 6, 2025	EX-5.3	Consent of Cooley LLP (included in Exhibit 5.3). Exhibit 5.3 Patrick Loofbourrow +1 (619) 840-4824 [email protected] August 6, 2025 Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 Ladies and Gentlemen: We have acted as U.S. counsel to Structure Therapeutics Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection with the filing by the Company of a Reg
August 6, 2025	EX-4.6	Form of Ordinary Share Warrant Agreement and Warrant Certificate.   Exhibit 4.6   Structure Therapeutics Inc.   and   , As Warrant Agent   Form of Ordinary Shares Warrant Agreement   Dated As Of         Structure Therapeutics Inc. Form of Ordinary Shares Warrant Agreement   This Ordinary Shares Warrant Agreement (this “Agreement”), dated as of [●], between Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the
August 6, 2025	EX-4.9	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 Structure Therapeutics Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Structure Therapeutics Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “C
August 6, 2025	EX-1.2	Sales Agreement, by and among Structure Therapeutics Inc., Leerink Partners LLC and Cantor Fitzgerald & Co., dated August 6, 2025. Exhibit 1.2 STRUCTURE THERAPEUTICS INC. American Depositary Shares Each Representing 3 Ordinary Shares ($0.0001 Par Value Per Ordinary Share) SALES AGREEMENT August 6, 2025 LEERINK PARTNERS LLC CANTOR FITZGERALD & CO. c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 c/o Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, NY 10022 Ladies and Gen
August 6, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-3 Structure Therapeutics Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward
August 6, 2025	S-3ASR	As filed with the Securities and Exchange Commission on August 6, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 6, 2025 Registration No.
June 25, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (C
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Str
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Com
May 8, 2025	EX-99.1	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin rec Exhibit 99.1 Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Asso
April 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
February 27, 2025	EX-19.1	Amended Insider Trading Policy. Exhibit 19.1 Structure Therapeutics Inc. Insider Trading Policy Policy Principles ● Employees, directors and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of Structure Therapeutics Inc. and its subsidiaries (together, the “Company”) are responsible for understanding the obligations that come with having access to material nonpublic information and wanting to
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Structur
February 27, 2025	S-8	As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.
February 27, 2025	EX-10.19	Amended Non-Employee Director Compensation Policy. Exhibit 10.19 Structure Therapeutics Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Structure Therapeutics Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy f
February 27, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 Structure Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, $0.0001 par value per share, issuable under the Structure Therapeutics Inc. 2023 Equity
February 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation
February 27, 2025	EX-99.1	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small mole Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation a
December 17, 2024	EX-99.1	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profil Exhibit 99.1 Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candid
December 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 Structure Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation
November 14, 2024	SC 13G/A	GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) / Avoro Capital Advisors LLC - STRUCTURE THERAPEUTICS INC. Passive Investment SC 13G/A 1 p24-3030sc13ga.htm STRUCTURE THERAPEUTICS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of T
November 14, 2024	EX-99.1	Exhibit 1:             Joint Filing Agreement EX-99.1 2 tm2427451d30ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
November 14, 2024	SC 13G/A	GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d30sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of th
November 13, 2024	EX-10.1	Separation and Consulting Agreement, dated September 12, 2024, by and between the Registrant and Mark Bach. Exhibit 10.1 STRUCTURE THERAPEUTICS, INC. September 12, 2024 Mark Bach, M.D., Ph.D. Via E-mail Re:Separation and Consulting Agreement Dear Mark: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Structure Therapeutics USA, Inc. (f/k/a ShouTi Inc.) (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your last da
November 13, 2024	EX-99.1	Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected Exhibit 99.1 Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund pr
November 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation
November 13, 2024	EX-10.2	Offer Letter, dated September 12, 2024, by and between the Registrant and Blai Coll. Exhibit 10.2 STRUCTURE THERAPEUTICS USA INC. September 12, 2024 Blai Coll, MD, Ph.D [*] Email: [*] Re:Employment Terms Dear Blai: Structure Therapeutics USA Inc. (the “Company”) is pleased to offer you continued employment under the terms set forth in this offer letter agreement, which, if accepted, will be effective on September 18, 2024 (the “Start Date”). Position Your position will be Chie
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608
November 13, 2024	EX-10.3	Offer Letter, dated September 7, 2024, by and between the Registrant and Ashley Hall. Exhibit 10.3 STRUCTURE THERAPEUTICS USA INC. September 7, 2024 Ashley Hall [***] Re:Employment Terms Dear Ashley: Structure Therapeutics USA Inc. (the “Company”) is pleased to offer you employment, which is anticipated to begin on September 18, 2024, under the terms set forth in this offer letter employment agreement (the “Agreement”). Your actual employment start date will be referred to herein a
November 12, 2024	SC 13G	GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Structure Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86366E106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Structure Therapeutics Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d
November 8, 2024	SC 13G/A	GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Structure Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86366E106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria
September 17, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)  of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporatio
September 17, 2024	EX-99.1	Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer Exhibit 99.1 Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer SAN FRANCISCO – September 17, 2024 – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardio
August 27, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Stru
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (C
August 8, 2024	EX-99.1	Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024 Oral small molecule amylin receptor agonist development candidate expected Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and
June 27, 2024	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Co
June 6, 2024	424B4	9,066,972 American Depositary Shares Representing 27,200,916 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-279915 Registration No. 333-279983 9,066,972 American Depositary Shares Representing 27,200,916 Ordinary Shares We are offering 9,066,972 American Depositary Shares (“ADSs”), representing 27,200,916 ordinary shares, par value $0.0001 per share. Each ADS represents three ordinary shares. Our ADSs are listed on the Nasdaq Glo
June 5, 2024	S-1MEF	As filed with the Securities and Exchange Commission on June 5, 2024. As filed with the Securities and Exchange Commission on June 5, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Structure Therapeutics Inc. (Exact name of Registrant as specified in its charter) Cayman Islands 2834 98-1480821 (State or other jurisdiction of incorporation or organiza
June 5, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 Structure Therapeutics Inc. Table 1 - Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2)(3) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(5) Equity Ordinary Shares, $0.0001 par value per share Rule 457(a) 3,681,051 $17.50
June 3, 2024	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 Structure Therapeutics Inc. [·] American Depositary Shares Representing [·] Ordinary Shares (Par Value $0.0001 Per Share) and Pre-Funded Warrants to Purchase [·] Ordinary Shares Represented by American Depositary Shares UNDERWRITING AGREEMENT June [·], 2024 Goldman Sachs & Co. LLC Morgan Stanley & Co. LLC Jefferies LLC Leerink Partners LLC As Representatives of the Several Underwriters
June 3, 2024	EX-4.5	Form of Pre-Funded Warrant. Exhibit 4.5 STRUCTURE THERAPEUTICS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Number of Warrant ADSs: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 2024 Structure Therapeutics Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), hereby certifies that, for good and valu
June 3, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 Structure Therapeutics Inc. Table 1 - Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2)(3) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price(3)(4)(5) Fee Rate Amount of Registration Fee(5) Equity Ordinary Shares, $0.0001 par value per share Rule 457(a) 27,600,0
June 3, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Com
June 3, 2024	CORRESP	June 3, 2024 June 3, 2024 Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Leerink Partners LLC 53 State Street, 40th Floor Boston, MA 02109 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re
June 3, 2024	EX-99.2	1 GSBR-1290 Obesity Topline Data Presentation June 2024 2 Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Refor Exhibit 99.2 1 GSBR-1290 Obesity Topline Data Presentation June 2024 2 Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, in
June 3, 2024	S-1	As filed with the Securities and Exchange Commission on June 3, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 3, 2024.
June 3, 2024	CORRESP	Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 June 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky RE: Structure Therapeutics Inc. Registration Statement on Form S-1 Filed June 3, 2024 File No. 333-279915 Acceleration Request Requested Date: June 5, 2024
June 3, 2024	EX-99.1	Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 GSBR-1290 achieved a clinically meaningful and statistically Exhibit 99.1 Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in capsule to ta
June 3, 2024	EX-5.3	Consent of Cooley LLP (included in Exhibit 5.3). Exhibit 5.3 June 3, 2024 Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 Ladies and Gentlemen: We have acted as U.S. counsel to Structure Therapeutics Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection with the filing of a Registration Statement on Form S-1 (the “Registration Statement”), includi
June 3, 2024	EX-99.1	As of the date of this Current Report, Structure Therapeutics Inc. (the “Company”) updates and Exhibit 99.1 As of the date of this Current Report, Structure Therapeutics Inc. (the “Company”) updates and supplements the risk factors disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 8, 2024 (“Annual Report”), as supplemented and updated by the risk factors disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter
June 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Com
May 31, 2024	CORRESP	Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: (858) 550-6000 f: (858) 550-6420 cooley.com Charles S. Kim +1 (858) 550-6049 [email protected] May 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Newberry, Lynn Dicker, Doris Stacey Gama, Joshua Gorsky Re: Structure Therapeutics Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-41608 Ladies and Gentlemen:
May 30, 2024	SC 13G	GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2416036d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106** (CUSIP Number) May 20, 2024 (Date of Event Which Requires Filing of this Statement) C
May 24, 2024	CORRESP	Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: (858) 550-6000 f: (858) 550-6420 cooley.com Charles S. Kim +1 (858) 550-6049 [email protected] May 24, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Newberry, Lynn Dicker, Doris Stacey Gama, Joshua Gorsky Re: Structure Therapeutics Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-41608 Ladies and Gentlemen:
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Comm
May 9, 2024	EX-10.2	Non-Employee Director Compensation Policy. Exhibit 10.2 Structure Therapeutics Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Structure Therapeutics Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy fo
May 9, 2024	EX-10.1	Executive Employment Agreement, dated July 22, 2022, by and between the registrant and Xichen Lin. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of July 22, 2022: A. Shanghai ShouTi Biotechnology Co.,
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Str
May 9, 2024	EX-99.1	Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to Exhibit 99.1 Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fi
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
March 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Co
March 8, 2024	S-8	As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No.
March 8, 2024	EX-97	Incentive Compensation Recoupment Policy. Structure Therapeutics Inc. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of Structure Therapeutics Inc., a company incorporated in the Cayman Islands (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s re
March 8, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Structur
March 8, 2024	EX-99.1	Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Year-end cash balance o
March 8, 2024	EX-21.1	Name of Subsidiary Name of Subsidiary Jurisdiction of Incorporation or Organization Annapurna Bio Pty Limited Australia Annapurna Bio, Inc.
March 8, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Structure Therapeutics Inc.
February 14, 2024	SC 13G/A	US86366E1064 / STRUCTURE THERAPEUTICS INC 0.00000000 / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-gpcr123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 86366E106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check
February 14, 2024	SC 13G	US86366E1064 / STRUCTURE THERAPEUTICS INC 0.00000000 / Avoro Capital Advisors LLC - STRUCTURE THERAPEUTICS INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 8, 2024	SC 13G	US86366E1064 / STRUCTURE THERAPEUTICS INC 0.00000000 / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Structure Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86366E106 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
February 6, 2024	SC 13G/A	US86366E1064 / STRUCTURE THERAPEUTICS INC 0.00000000 / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Structure Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86366E106 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
December 20, 2023	SC 13G/A	US86366E1064 / STRUCTURE THERAPEUTICS INC 0.00000000 / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106 (CUSIP
December 18, 2023	EX-99.2	GSBR - 1290 Comprehensive Program Update CONFIDENTIAL December 18, 2023 Exhibit 99.2 GSBR - 1290 Comprehensive Program Update CONFIDENTIAL December 18, 2023 2 Attendees • Raymond Stevens, Ph.D., Chief Executive Officer • Mark Bach, M.D., Ph.D., Chief Medical Officer • Blai Coll, M.D., Ph.D., VP Clinical Development • Jun Yoon, Chief Financial Officer • Danielle Keatley, Investor Relations Confidential 3 Forward looking statements This presentation contains “forward -
December 18, 2023	EX-99.1	Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 Exhibit 99.1 Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to a
December 18, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation)
November 27, 2023	CORRESP	Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, CA 94080 November 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Structure Therapeutics Inc. Registration Statement on Form S-1 Filed November 17, 2023 File No. 333-275651 Acceleration Request Requested Date: Nov
November 20, 2023	DRS	As confidentially submitted to the Securities and Exchange Commission on November 20, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confiden TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on November 20, 2023.
November 17, 2023	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Name of Subsidiary Jurisdiction of Incorporation or Organization Aconcagua Bio, Inc. Delaware Annapurna Bio, Inc. Delaware Basecamp Bio Inc. Cayman Islands Gasherbrum Bio, Inc. Delaware Gimigela Bio, Inc. Delaware Lhotse Bio, Inc. Delaware Shanghai ShouTi Biotechnology Co., Ltd. (上海硕迪生物技术有限公司) People’s Republic of China ShouTi Hong Kong Limited Hong Kong Structure Therapeutics USA Inc
November 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608
November 17, 2023	EX-10.4	Share Purchase Agreement, dated as of September 29, 2023, by and among the registrant and the purchasers named therein. Exhibit 10.4 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of September 29, 2023, by and among Structure Therapeutics, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and co
November 17, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 2) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 2) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file nu
November 17, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Structure Therapeutics Inc.
November 17, 2023	S-1	As filed with the Securities and Exchange Commission on November 17, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 17, 2023 Registration No.
November 16, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file nu
November 14, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation)
November 14, 2023	EX-99.1	Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily d Exhibit 99.1 Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tolerability profile Topline data from GSBR-1290 Phase 2a diabetes cohort expected in December 2023;
November 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-41608 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-41608 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report
November 14, 2023	EX-10.1	Collaboration Agreement, dated November 7, 2023, by and between Schrödinger, Inc. and Aconcagua Bio, Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is effective as of November 7, 2023 (the “Effective Date”) by and between Schrödinger, Inc., a Delaware cor
September 29, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation
September 29, 2023	EX-99.1	Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase Exhibit 99.1 Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily dosing Topline data from Phase 2a type 2 diabe
September 29, 2023	EX-99.2	Structure Therapeutics Announces $300 Million Private Placement Equity Financing $300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with ex Exhibit 99.2 Structure Therapeutics Announces $300 Million Private Placement Equity Financing $300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents and short-term investments, are expected to extend cash runway through the end of 2026 SAN FRANCISCO – Sept
September 29, 2023	EX-99.1	SHARE PURCHASE AGREEMENT Exhibit 99.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of September 29, 2023, by and among Structure Therapeutics, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and co
September 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation
September 29, 2023	EX-99.2	Attendees • Raymond Stevens, Ph.D., Chief Executive Officer • Mark Bach, M.D., Ph.D., Chief Medical Officer • Blai Coll, M.D., Ph.D., VP Clinical Development • Jun Yoon, Chief Financial Officer • Danielle Keatley, Investor Relations Forward looking s Exhibit 99.2 GSBR-1290 Phase 1b MAD Results September 29, 2023 Attendees • Raymond Stevens, Ph.D., Chief Executive Officer • Mark Bach, M.D., Ph.D., Chief Medical Officer • Blai Coll, M.D., Ph.D., VP Clinical Development • Jun Yoon, Chief Financial Officer • Danielle Keatley, Investor Relations Forward looking statements This presentation contains “forward-looking statements” within the meaning of
August 10, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (
August 10, 2023	EX-99.1	Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO – August 10, 2023 – Structure Therapeutics Inc. (NASDAQ: GPCR),
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Stru
August 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Structure Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (C
August 4, 2023	EX-10.1	Non-employee Director Compensation Policy Exhibit 10.1 Structure Therapeutics Inc. Non-Employee Director Compensation Policy Effective Date: February 2, 2023 Amended by the Board: August 3, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Structure Therapeutics Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe
July 6, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Co
July 6, 2023	EX-10.2	House Leasing Contract, dated June 29, 2023, by and between the Shanghai ShouTi Biotechnology Co., ltd. and Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. Exhibit 10.2 Contract No.: Concora SPACE - Structure House Leasing Contract Between [Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.] And [Shanghai ShouTi Biotechnology Co., Ltd.] House Leasing Contract 1 House Leasing Contract This House Leasing Contract is made as of June 29, 2023, by and between: Party A (Lessor): Shanghai Chuangzhi Space Entrepreneurship Incubator Mana
July 6, 2023	EX-10.3	Sublease, dated June 29, 2023, by and between Structure Therapeutics USA Inc. and Aligos Therapeutics, Inc. Exhibit 10.3 SUBLEASE THIS SUBLEASE ("Sublease"), dated as of June 29, 2023, is made by and between Aligos Therapeutics, Inc., a Delaware corporation ("Sublandlord”), and Structure Therapeutics USA Inc., a Delaware corporation ("Subtenant"). Sublandlord and Subtenant hereby agree as follows: 1. Recitals: This Sublease is made with reference to the following facts, intentions and understandings: A.
July 6, 2023	EX-10.1	Lease Agreement, dated June 29, 2023, by and between the registrant and Shanghai Changtai Business Management Co., Ltd. Exhibit 10.1 SHANGHAI PREMISES LEASE CONTRACT Important Notice 1.      This Contract applies to issues in respect of pre-lease of commercial housing situated within the administrative jurisdiction and of such premises the rent of which is determined by related parties by means of negotiation on the reasonable market value basis, which both kinds of properties or premises exclude any publicly-owned
June 5, 2023	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Com
June 5, 2023	EX-16.1	Letter from PricewaterhouseCoopers LLP to the SEC, dated June 5, 2023 Exhibit 16.1 June 5, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Structure Therapeutics Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Structure Therapeutics Inc. dated May 31, 2023. We agree with the statements concerning
May 11, 2023	EX-99.1	Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studie Exhibit 99.1 Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2023 SAN FRANCISCO and SHANGHAI – May 11, 2023 – Structure Therapeutics Inc. (NASDAQ: GPCR), a cli
May 11, 2023	EX-10.1	Exchange Agreement dated May 10, 2023 between the registrant and the investors named therein Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this “Agreement”) is made as of May 10, 2023, by and among the investors listed on Exhibit A attached hereto (each an “Investor” and together, the “Investors”) and Structure Therapeutics Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”). RECITALS A. Each Investor holds that number of the
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the three months ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Structu
May 11, 2023	EX-4.5	Summary of Rights of Non-Voting Ordinary Shares. Exhibit 4.5 SUMMARY OF Rights of Non-Voting Ordinary Shares Voting Rights. Non-Voting Ordinary Shares (“Non-Voting Ordinary Shares”) (i) shall confer upon the shareholder no right to receive notice of, to attend, to speak at nor to vote at general meetings of Structure Therapeutics Inc. (the “Company”) except as may be required by law and (ii) for the avoidance of doubt, shall not entitle the hold
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (Com
March 30, 2023	EX-21.1	Subsidiaries of the registrant. Name of Subsidiary Jurisdiction of Incorporation or Organization Annapurna Bio Pty Limited Australia Annapurna Bio, Inc.
March 30, 2023	EX-99.1	Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290 Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 20 Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290 Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023 Completed $185.3 million upsized initial public offering SAN FRANCISCO and SHANGHAI – March 30, 2023 – Structure Therapeutics Inc. (NA
March 30, 2023	EX-10.3	Structure Therapeutics Inc. 2023 Equity Incentive Plan. Structure Therapeutics Inc. 2023 Equity Incentive Plan Adopted by the Board of Directors: January 11, 2023 Approved by the Shareholders: January 19, 2023 IPO Date: February 2, 2023 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan, (ii) th
March 30, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation) (C
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41608 Structur
March 30, 2023	EX-4.5	Exhibit 4.5 Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Structure Therapeutics Inc., or “we,” “us,” and “our,” had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act, as amended (the “Exchange Act”): Title of Each Class Trading Symbol(s) Name of Each Exchange On Which Registered American Depositary Shares (ADSs), eac
March 30, 2023	EX-10.9	Structure Therapeutics Inc. 2023 Employee Share Purchase Plan. Structure Therapeutics Inc. 2023 Employee Share Purchase Plan Adopted by the Board of Directors: January 11, 2023 Approved by the Shareholders: January 19, 2023 IPO Date: February 2, 2023 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company
February 13, 2023	SC 13G	BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 86366E106 (CUSIP N
February 13, 2023	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g07422gpcr02132023.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 13, 2023 with respect to the Ordinary Shares, par value $0.0001 per share, of Structure Therapeutics Inc., a Cayman Islands corporation, and any further amendments thereto executed by each and any of the undersigned shal
February 10, 2023	SC 13G	FMR LLC SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 STRUCTURE THERAPEUTICS INC COMMON STOCK Cusip #JQD059000 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #JQD059000 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,414,556 Item 6: 0 Item 7: 9,414,556 Item 8: 0 It
February 7, 2023	EX-3.1	Amended and Restated Memorandum and Articles of Association of the registrant. Exhibit 3.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF STRUCTURE THERAPEUTICS INC. (adopted by a Special Resolution passed on January 19, 2023 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing the Company’s Ordinary Sh
February 7, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-41608 98-1480821 (State or other jurisdiction of incorporation)
February 6, 2023	424B4	10,740,000 American Depositary Shares Representing 32,220,000 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-269200 Registration No. 333-269542 PROSPECTUS 10,740,000 American Depositary Shares Representing 32,220,000 Ordinary Shares We are offering 10,740,000 American depositary shares, or ADSs, representing 32,220,000 ordinary shares, par value $0.0001 per share. Each ADS represents three ordinary shares. This is our initial publ
February 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Structure Therapeutics Inc.
February 6, 2023	S-8	As filed with the Securities and Exchange Commission on February 6, 2023 As filed with the Securities and Exchange Commission on February 6, 2023 Registration No.
February 3, 2023	SC 13G	Deep Track Capital, LP SC 13G 1 deeptrack-gpcr020323.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Structure Therapeutics Inc. (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 86366E106 (CUSIP Number) February 3, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr
February 2, 2023	S-1MEF	As filed with the Securities and Exchange Commission on February 2, 2023. S-1MEF 1 tm225197d18s1mef.htm FORM S-1MEF As filed with the Securities and Exchange Commission on February 2, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Structure Therapeutics Inc. (Exact name of Registrant as specified in its charter) Cayman Islands 2834 98-1480821 (State or o
February 2, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 Structure Therapeutics Inc. Table 1 - Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Fees to Be Paid Equity Ordinary Shares, $0.0001 par value per share Rule 457(o) — — $ 3
January 31, 2023	CORRESP	STRUCTURE THERAPEUTICS INC. 611 Gateway Blvd., Suite 223 South San Francisco, CA 94080 STRUCTURE THERAPEUTICS INC. 611 Gateway Blvd., Suite 223 South San Francisco, CA 94080 January 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson Terence O’Brien Jimmy McNamara Joe McCann Re: Structure Therapeutics Inc. Registration Statement on Form S-1, as amended (File No. 333-269200) Reque
January 31, 2023	CORRESP	January 31, 2023 January 31, 2023 Jefferies LLC 520 Madison Avenue New York, New York 10022 SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 BMO Capital Markets Corp.
January 30, 2023	EX-99.(A)	TABLE OF CONTENTS J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 1 (e) Commission 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 2 (k) Holder 2 (l) Removal Notice Date 3 (m) Resignation Notice D
January 30, 2023	EX-3.2	Form of Amended and Restated Memorandum and Articles of Association of the Registrant, effective immediately upon the closing of the Registrant’s initial public offering (incorporated herein by reference to Exhibit 3.2 to the Registration Statement on Form S-1, as amended (File No. 333-269200)). Exhibit 3.2 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF STRUCTURE THERAPEUTICS INC. (adopted by a Special Resolution passed on January 19, 2023 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing the Company’s Ordinary Sh
January 30, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 30, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 30, 2023.
January 30, 2023	EX-99.(D)	Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, Suite 2405 New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 January 30, 2023 Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, Suite 2405 New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 January 30, 2023 JPMorgan Chase Bank, N.
January 30, 2023	8-A12B	Form 8-A 8-A12B 1 tm234457d18a12b.htm FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (State or other jurisdiction of incorporation o
January 30, 2023	EX-4.2	Form of American Depositary Receipt evidencing American Depositary Shares (included in Exhibit 4.2). Exhibit 4.2 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions 1 (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 1 (e) Commission 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 2 (k) Holder 2 (l) Removal Notice Date 3 (m) Resignation Notice Date 3 (n
January 30, 2023	EX-4.1	Registrant’s Specimen Certificate for Ordinary Shares. Exhibit 4.1 Structure Therapeutics Inc. - Ordinary Shares (Incorporated under the laws of the Cayman Islands) Number Shares Share Capital is US$60,000 divided into 600,000,000 shares consisting of (i) 500,000,000 Ordinary Shares of a par value of US$0.0001 each; (ii) 100,000,000 undesignated shares of a par value of US$0.0001 each, of such class or classes (however designated) as the board of dire
January 30, 2023	F-6	As filed with the U.S. Securities and Exchange Commission on January 30, 2023 As filed with the U.S. Securities and Exchange Commission on January 30, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Structure Therapeutics Inc. (Exact name of issuer of deposited securities as specified in its chart
January 30, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 Structure Therapeutics Inc. Table 1 - Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(2)(3) Fee Rate Amount of Registration Fee(3) Fees to Be Paid Equity Ordinary Shares, $0.0001 par value per share Rule 457(o) — —
January 30, 2023	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 Structure Therapeutics Inc. [●] American Depositary Shares Representing [●] Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT February [●], 2023 JEFFERIES LLC SVB SECURITIES LLC GUGGENHEIM SECURITIES, LLC BMO CAPITAL MARKETS CORP. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Securities LLC 53 Sta
January 23, 2023	CORRESP	FOIA Confidential Treatment Request Confidential Treatment Requested by Structure Therapeutics Inc. in connection with its Registration Statement on Form S-1 (File No. 333-269200) Patrick Loofbourrow +1 (619) 840-4824 [email protected] BY EDGAR FOIA Confidential Treatment Request Confidential Treatment Requested by Structure Therapeutics Inc. in connection with its Registration Statement on Form S-1 (File No. 333-269200) January 23, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson
January 12, 2023	EX-10.19	Board Service Agreement by and between the registrant and Sharon Tetlow, dated March 2, 2022. Exhibit 10.19 March 2, 2022 Sharon Tetlow [*] [*] Dear Sharon: We are delighted that you have agreed to join the Board of Directors (the “Board”) of ShouTi Inc. (the “Company”) and to serve as the Chair of the Audit Committee of the Board (the “Audit Chair”). This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1. Appointment as Bo
January 12, 2023	EX-10.11	Executive Employment Agreement by and between the registrant and Jun Yoon, dated May 1, 2019. Exhibit 10.11 SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT for JUN YOON This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of May 1, 2019 (the “Effective Date”), by and between Jun Yoon (“Employee”) and ShouTi Inc., a Delaware corporation (the “Company”). 1.              Employment by the Company. 1.1            Position. Employee shall serve as the Company
January 12, 2023	EX-10.17	Supplemental Agreement, by and among Shanghai Basecamp Biotechnology Co., Ltd., Shanghai ShouTi Biotechnology Co., Ltd. and Yingli Ma, dated October 31, 2022. Exhibit 10.17 Supplemental Agreement Shanghai Basecamp Biotechnology Co., Ltd. (hereinafter referred to as “Shanghai Basecamp”), a corporation formally organized and validly existing under the laws of the PRC with its address of Room 5-129, No5-123, South Building 1, No. 4560 Jinke Road, China (Shanghai) Pilot Free Trade Zone and legal representative of RAYMOND CHARLES STEVENS; And Shanghai Shouti
January 12, 2023	EX-10.10	Executive Employment Agreement, by and between the registrant and Raymond Stevens, dated May 16, 2019. Exhibit 10.10 SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT for RAYMOND STEVENS This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of May 16, 2019 (the “Effective Date”), by and between Raymond Stevens (“Employee”) and ShouTi Inc., a Delaware corporation (the “Company”). 1. Employment by the Company. 1.1 Position. Employee shall serve as the Company’s Chief
January 12, 2023	EX-10.25	Shanghai Premises Lease Contract, by and between Shanghai ShouTi Biotechnology Co., Ltd. and Shanghai Changtai Business Management Co., Ltd., dated June 22, 2021. Exhibit 10.25 SHANGHAI PREMISES LEASE CONTRACT Important Notice 1. This Contract applies to issues in respect of pre-lease of commercial housing situated within the administrative jurisdiction and of such premises the rent of which is determined by related parties by means of negotiation on the reasonable market value basis, which both kinds of properties or premises exclude any publicly-owned res
January 12, 2023	EX-10.3	Structure Therapeutics Inc. 2023 Equity Incentive Plan Exhibit 10.3 Structure Therapeutics Inc. 2023 Equity Incentive Plan Adopted by the Board of Directors: [] Approved by the Shareholders: [] IPO Date: [] 1.            General. (a)               Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan, (ii) the
January 12, 2023	EX-10.6	Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (PRC) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan.   Exhibit 10.6    PRC Form Share Option Grant Package   Structure Therapeutics Inc. Share Option Grant Notice (2023 Equity Incentive Plan)   Structure Therapeutics Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”) and this Share Option Grant Notice, has granted to you (“Optionholder”) an option to purchase the number of Shares set forth below (the “Option”). Your Option
January 12, 2023	EX-10.1	Form of Indemnification Agreement between the registrant and each of its executive officers and directors. Exhibit 10.1 STRUCTURE THERAPEUTICS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of , by and between Structure Therapeutics Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and [Name of Director/Officer] ([US passport/ID]:[*]) Whereas, the Indemnitee has agreed to serve as a director or officer
January 12, 2023	EX-10.5	Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (Non-Employee Director) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan. Exhibit 10.5 U.S. Form Director Share Option Grant Package Structure Therapeutics Inc. Share Option Grant Notice (2023 Equity Incentive Plan) Structure Therapeutics Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”) and this Share Option Grant Notice, has granted to you (“Optionholder”) an option to purchase the number of Shares set forth below (the “Option”). Your Optio
January 12, 2023	EX-10.4	Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (US) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan. Exhibit 10.4 U.S. Form Share Option Grant Package Structure Therapeutics Inc. Share Option Grant Notice (2023 Equity Incentive Plan) Structure Therapeutics Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”) and this Share Option Grant Notice, has granted to you (“Optionholder”) an option to purchase the number of Shares set forth below (the “Option”). Your Option is subj
January 12, 2023	EX-10.22	Non-Employee Director Compensation Policy. Exhibit 10.22 Structure Therapeutics Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Structure Therapeutics Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy f
January 12, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-1 Structure Therapeutics Inc. Table 1 - Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(2)(3) Fee Rate Amount of Registration Fee(3) Equity Ordinary Shares, $0.0001 par value per share Rule 457(o) — — $100,000,000 0.0
January 12, 2023	EX-10.12	Amendment to the Executive Employment Agreement by and between the registrant and Jun Yoon. Exhibit 10.12 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made and entered into as of December 5, 2022 by and between Structure Therapeutics USA Inc., a Delaware corporation (the “Company”), and Jun Yoon, an individual resident in the State of California (the “Employee”) (the Company and the Employee are hereinafter som
January 12, 2023	EX-10.7	Form of Restricted Share Unit Award Grant Notice and Award Agreement (US) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan. Exhibit 10.7 U.S. Form RSU Grant Package Structure Therapeutics Inc. RSU Award Grant Notice (2023 Equity Incentive Plan) Structure Therapeutics Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted share units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as
January 12, 2023	EX-3.1	Amended and Restated Memorandum and Articles of Association of the registrant, as currently in effect. Exhibit 3.1 THE COMPANIES ACT COMPANY LIMITED BY SHARES SIXTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF STRUCTURE THERAPEUTICS INC. (adopted by a special resolution dated June 30, 2022) 1. The name of the Company is Structure Therapeutics Inc. 2. The Registered Office of the Company shall be at the offices of International Corporation Services Ltd., PO Box 472, 2nd Floor, Harbour Place, 10
January 12, 2023	EX-4.4	Amended and Restated Investors’ Rights Agreement, dated July 30, 2021, by and between the registrant and the investors named therein. Exhibit 4.4 SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 30, 2021, by and among ShouTi Inc., an exempted company limited by shares incorporated under the laws of the Cayman Islands (the “Company”), and the investors set forth in Schedule A attached hereto (each, an “Investor” and collectively,
January 12, 2023	EX-10.9	Structure Therapeutics Inc. 2023 Employee Share Purchase Plan. Exhibit 10.9 Structure Therapeutics Inc. 2023 Employee Share Purchase Plan Adopted by the Board of Directors: [] Approved by the Shareholders: [] IPO Date: [] 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company to grant a series of Purch
January 12, 2023	EX-10.23	Severance and Change in Control Plan.   Exhibit 10.23   Structure Therapeutics Inc. Severance and Change in Control Plan   Section 1.              Introduction.   The Structure Therapeutics Inc. Severance and Change in Control Plan (the “Plan”) is hereby established by the Board of Directors of the Company effective upon the IPO Date (each as defined below). The purpose of the Plan is to provide for severance and/or Change in Control
January 12, 2023	EX-10.21	Board Service Agreement by and between the registrant and Eric Dobmeier, dated December 13, 2022. Exhibit 10.21 December 12, 2022 Eric Dobmeier Dear Eric: We are delighted that you have agreed to join the Board of Directors (the “Board”) of Structure Therapeutics Inc. (the “Company”). This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1. Appointment as Board Member. Your service as a Board member will be effective as of the date
January 12, 2023	EX-10.20	Board Service Agreement by and between the registrant and Joanne Waldstreicher, dated November 23, 2022. Exhibit 10.20 November 23, 2022 Joanne Waldstreicher [***] Dear Joanne: We are delighted that you have agreed to join the Board of Directors (the “Board”) of Structure Therapeutics Inc. (the “Company”). This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1. Appointment as Board Member. Your service as a Board member will be effective
January 12, 2023	EX-10.2	ShouTi Inc. 2019 Equity Incentive Plan, as amended (including Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder). Exhibit 10.2 U.S. ShouTi Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2019 Approved by the Shareholders: April 18, 2019 Termination Date: April 17, 2029 1.             General. (a)            Eligible Share Award Recipients. Employees, Directors and Consultants are eligible to receive Share Awards. (b)            Available Share Awards. The Plan provides for the gra
January 12, 2023	EX-10.16	Employment Contract, by and between Shanghai ShouTi Biotechnology Co., Ltd. and Yingli Ma, dated November 1, 2022. Exhibit 10.16 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of November 1, 2022： A. Shanghai ShouTi Biotechnology Co., Ltd., a wholly foreign-owned enterprise duly organized and validly existing under the laws of the People’s Republic of China (the “PRC”), with its registered address at Rooms 502, Building 1, No.2889 Jinke
January 12, 2023	EX-10.14	Offer Letter, by and between the registrant and Melita Sun Jung, dated April 23, 2021. Exhibit 10.14 April 23, 2021 Melita Sun Jung Email: [***] Re: Amended and Restated Offer of Employment Dear Melita: As you know, ShouTi Inc., a Delaware corporation (the “Company”), entered into an employment offer letter with you on February 14, 2021 (the “Offer Letter”). You and the Company hereby agree to amend and restate the Offer Letter. The terms and conditions set forth in this letter agre
January 12, 2023	EX-10.18	Board Service Agreement by and between the registrant and Daniel Welch, dated December 10, 2021. Exhibit 10.18 December 10th, 2021 Daniel Welch [*] [*] Dear Dan: We are delighted that you have agreed to join the Board of Directors (the “Board”) of ShouTi Inc. (the “Company”) and to serve as the Chairman of the Board. This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1.            Appointment as Board Member. Your service as
January 12, 2023	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Name of Subsidiary Jurisdiction of Incorporation or Organization Annapurna Bio Pty Limited Australia Annapurna Bio, Inc. Delaware Basecamp Bio Hong Kong Limited Hong Kong Basecamp Bio Inc. Cayman Islands Basecamp Bio USA Inc. Delaware Gasherbrum Bio, Inc. Delaware Lhotse Bio, Inc. Delaware Shanghai Basecamp Biotechnology Co., Ltd. (上海倍勘生物技术有限公司) People’s Republic of China Shanghai Sho
January 12, 2023	EX-10.8	Form of Restricted Share Unit Award Grant Notice and Award Agreement (PRC) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan.   Exhibit 10.8   PRC Form RSU Grant Package   Structure Therapeutics Inc. RSU Award Grant Notice (2023 Equity Incentive Plan)   Structure Therapeutics Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted share units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and condit
January 12, 2023	EX-10.13	Offer Letter, by and between the registrant and Mark Bach, M.D., dated April 19, 2021. Exhibit 10.13 April 19, 2021 Mark Bach, M.D. E-mail: [***] Re: Offer of Employment Dear Dr. Bach: ShouTi Inc., a Delaware corporation (the “Company”), is pleased to offer you employment on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Employment by the Company. 1.1 Position. You will serve as the Company’s Chief Medical Officer, reporting the Company’s Chief Exe
January 12, 2023	CORRESP	Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: (858) 550-6000 f: (858) 550-6420 cooley.com Patrick Loofbourrow +1 (619) 840-4824 [email protected] January 12, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson, Terence O’Brien, Jimmy McNamara, Joe McCann Re: Structure Therapeutics Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted December 5, 2022 CIK No. 0001888886 Ladies a
January 12, 2023	EX-10.15	Employment Contract, by and between Shanghai ShouTi Biotechnology Co., Ltd. and Xichen Lin, dated July 22, 2019. Exhibit 10.15 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of July 22, 2019: A. Shanghai ShouTi Biotechnology Co., Ltd., a wholly foreign-owned enterprise duly organized and validly existing under the laws of the People’s Republic of China (the “PRC”), with its registered address at Room 5-148, No. 1 South building of Jin
January 12, 2023	S-1	As filed with the Securities and Exchange Commission on January 12, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 12, 2023.
January 12, 2023	EX-10.24	Collaboration Agreement, by and between Lhotse Bio, Inc. and Schrödinger, LLC, dated October 9, 2020. Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is effective as of October 9, 2020 (the “Effective Date”) by and between Schrödinger, LLC, a Delaware limite
December 6, 2022	EX-10.1	STRUCTURE THERAPEUTICS INC. INDEMNIFICATION AGREEMENT EX-10.1 2 filename2.htm Exhibit 10.1 STRUCTURE THERAPEUTICS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of , by and between Structure Therapeutics Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and [Name of Director/Officer] ([US passport/ID]:[*]) Whereas, the Indemnitee has agreed to serve a
December 6, 2022	EX-10.12	Supplemental Agreement EX-10.12 5 filename5.htm Exhibit 10.12 Supplemental Agreement Shanghai Basecamp Biotechnology Co., Ltd. (hereinafter referred to as “Shanghai Basecamp”), a corporation formally organized and validly existing under the laws of the PRC with its address of Room 5-129, No5-123, South Building 1, No. 4560 Jinke Road, China (Shanghai) Pilot Free Trade Zone and legal representative of RAYMOND CHARLES STE
December 6, 2022	EX-21.1	EX-21.1 Exhibit 21.1 Name of Subsidiary Jurisdiction of Incorporation or Organization Annapurna Bio Pty Limited Australia Annapurna Bio, Inc. Delaware Basecamp Bio Hong Kong Limited Hong Kong Basecamp Bio Inc. Cayman Islands Basecamp Bio USA Inc. Delaware Gasherbrum Bio, Inc. Delaware Lhotse Bio, Inc. Delaware Shanghai Basecamp Biotechnology Co., Ltd. (上海倍勘生物技术有限公司) People’s Republic of China Shanghai Sho
December 6, 2022	EX-10.7	AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT EX-10.7 3 filename3.htm Exhibit 10.7 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made and entered into as of December 5, 2022 by and between Structure Therapeutics USA Inc., a Delaware corporation (the “Company”), and Jun Yoon, an individual resident in the State of California (the “Employee”) (the Company and the Emplo
December 6, 2022	EX-10.11	EMPLOYMENT CONTRACT EX-10.11 4 filename4.htm Exhibit 10.11 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of November 1, 2022： A. Shanghai ShouTi Biotechnology Co., Ltd., a wholly foreign-owned enterprise duly organized and validly existing under the laws of the People’s Republic of China (the “PRC”), with its registered address at Rooms 502,
December 6, 2022	DRS/A	As confidentially submitted to the Securities and Exchange Commission on December 5, 2022. This Amendment No. 2 to the Draft Registration Statement has not been publicly filed with the Securities and Exchange Commission and all information herein rem DRS/A 1 filename1.htm TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on December 5, 2022. This Amendment No. 2 to the Draft Registration Statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wa
December 5, 2022	DRSLTR	Cooley LLP 4401 Eastgate Mall San Diego, CA 92121-1909 t: (858) 550-6000 f: (858) 550-6420 cooley.com Patrick Loofbourrow +1 (619) 840-4824 [email protected] December 5, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson, Terence O’Brien, Gary Guttenberg, Christopher Edwards Re: Structure Therapeutics Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted May 13, 2022 CIK No. 0001888886 La
May 13, 2022	DRS/A	As confidentially submitted to the Securities and Exchange Commission on May 12, 2022. This Amendment No. 1 to the Draft Registration Statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains DRS/A 1 filename1.htm TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on May 12, 2022. This Amendment No. 1 to the Draft Registration Statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washin
May 13, 2022	EX-10.13	1 Exhibit 10.13 March 2, 2022 Sharon Tetlow [*] [*] Dear Sharon: We are delighted that you have agreed to join the Board of Directors (the “Board”) of ShouTi Inc. (the “Company”) and to serve as the Chair of the Audit Committee of the Board (the “Audit Chair”). This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1. Appointment as Bo
May 12, 2022	DRSLTR	Cooley LLP 4401 Eastgate Mall San Diego, CA 92121-1909 t: (858) 550-6000 f: (858) 550-6420 cooley.com DRSLTR 1 filename1.htm James Lu +1 (858) 550-6101 [email protected] May 12, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson, Terence O’Brien, Gary Guttenberg, Christopher Edwards Re: ShouTi Inc. Draft Registration Statement on Form S-1 Submitted February 14, 2022 CIK No. 0001888886 Ladies and Gentlemen: On
February 14, 2022	EX-10.2	ShouTi Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2019 Approved by the Shareholders: April 18, 2019 Termination Date: April 17, 2029 Exhibit 10.2 U.S. ShouTi Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2019 Approved by the Shareholders: April 18, 2019 Termination Date: April 17, 2029 1.             General. (a)            Eligible Share Award Recipients. Employees, Directors and Consultants are eligible to receive Share Awards. (b)            Available Share Awards. The Plan provides for the gra
February 14, 2022	EX-10.12	December 10th, 2021 EX-10.12 12 filename12.htm Exhibit 10.12 December 10th, 2021 Daniel Welch [*] [*] Dear Dan: We are delighted that you have agreed to join the Board of Directors (the “Board”) of ShouTi Inc. (the “Company”) and to serve as the Chairman of the Board. This letter sets forth the agreement between you and the Company regarding your Board membership (the “Agreement”): 1.            Appointment as Bo
February 14, 2022	EX-10.8	[Signature Page Follows] EX-10.8 8 filename8.htm Exhibit 10.8 April 23, 2021 Melita Sun Jung Email: [***] Re: Amended and Restated Offer of Employment Dear Melita: As you know, ShouTi Inc., a Delaware corporation (the “Company”), entered into an employment offer letter with you on February 14, 2021 (the “Offer Letter”). You and the Company hereby agree to amend and restate the Offer Letter. The terms and conditions set fo
February 14, 2022	EX-10.7	[Signature Page Follows] EX-10.7 7 filename7.htm Exhibit 10.7 April 19, 2021 Mark Bach, M.D. E-mail: [***] Re: Offer of Employment Dear Dr. Bach: ShouTi Inc., a Delaware corporation (the “Company”), is pleased to offer you employment on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Employment by the Company. 1.1 Position. You will serve as the Company’s Chief Medical Officer, reporting
February 14, 2022	EX-10.11	EMPLOYMENT CONTRACT Exhibit 10.11 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of May 11, 2021： A. Shanghai Basecamp Biotechnology Co., Ltd., a wholly foreign-owned enterprise duly organized and validly existing under the laws of the People’s Republic of China (the “PRC”), with its registered address at Room 5-123 and 5-129, No.1 South build
February 14, 2022	EX-10.15	SHANGHAI PREMISES LEASE CONTRACT Important Notice EX-10.15 14 filename14.htm Exhibit 10.15 SHANGHAI PREMISES LEASE CONTRACT Important Notice 1. This Contract applies to issues in respect of pre-lease of commercial housing situated within the administrative jurisdiction and of such premises the rent of which is determined by related parties by means of negotiation on the reasonable market value basis, which both kinds of properties or premises exc
February 14, 2022	DRS	As confidentially submitted to the Securities and Exchange Commission on February 14, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confiden DRS 1 filename1.htm TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on February 14, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FOR
February 14, 2022	EX-4.4	SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 4.4 SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 30, 2021, by and among ShouTi Inc., an exempted company limited by shares incorporated under the laws of the Cayman Islands (the “Company”), and the investors set forth in Schedule A attached hereto (each, an “Investor” and collectively,
February 14, 2022	EX-10.5	SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT RAYMOND STEVENS EX-10.5 5 filename5.htm Exhibit 10.5 SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT for RAYMOND STEVENS This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of May 16, 2019 (the “Effective Date”), by and between Raymond Stevens (“Employee”) and ShouTi Inc., a Delaware corporation (the “Company”). 1. Employment by the Company. 1.1 Position. Employee shall serve
February 14, 2022	EX-10.14	COLLABORATION AGREEMENT Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is effective as of October 9, 2020 (the “Effective Date”) by and between Schrödinger, LLC, a Delaware limite
February 14, 2022	EX-3.1	THE COMPANIES ACT COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF SHOUTI INC. (adopted by a special resolution dated July 30, 2021, and effective on July 30, 2021) Exhibit 3.1 THE COMPANIES ACT COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF SHOUTI INC. (adopted by a special resolution dated July 30, 2021, and effective on July 30, 2021) 1. The name of the Company is ShouTi Inc. 2. The Registered Office of the Company shall be at the offices of International Corporation Services Ltd., PO Box 472, 2nd Floor, Harbour Place, 1
February 14, 2022	EX-10.6	SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT JUN YOON EX-10.6 6 filename6.htm Exhibit 10.6 SHOUTI INC. EXECUTIVE EMPLOYMENT AGREEMENT for JUN YOON This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of May 1, 2019 (the “Effective Date”), by and between Jun Yoon (“Employee”) and ShouTi Inc., a Delaware corporation (the “Company”). 1.              Employment by the Company. 1.1            Position. Employee sha
February 14, 2022	EX-10.10	EMPLOYMENT CONTRACT EX-10.10 10 filename10.htm Exhibit 10.10 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Contract”) is entered into by and between the following parties on as of July 22, 2019: A. Shanghai ShouTi Biotechnology Co., Ltd., a wholly foreign-owned enterprise duly organized and validly existing under the laws of the People’s Republic of China (the “PRC”), with its registered address at Room 5-148,
February 14, 2022	EX-10.9	[Signature Page Follows] EX-10.9 9 filename9.htm Exhibit 10.9 November 24, 2021 Ding Ding, Ph.D. E-mail: [***] Re: Offer of Employment Dear Ding Ding: ShouTi Inc., a Delaware corporation (the “Company”), is pleased to offer you employment on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Employment by the Company. 1.1 Position. You will serve as the Company’s Chief Financial Officer, rep
February 14, 2022	EX-21.1	EX-21.1 Exhibit 21.1 Name of Subsidiary Jurisdiction of Incorporation or Organization Annapurna Bio Pty Limited Australia Annapurna Bio, Inc. Delaware Basecamp Bio Hong Kong Limited Hong Kong Basecamp Bio Inc. Cayman Islands Basecamp Bio USA Inc. Delaware Gasherbrum Bio, Inc. Delaware Lhotse Bio, Inc. Delaware Shanghai Basecamp Biotechnology Co., Ltd. (上海倍勘生物技术有限公司) People’s Republic of China Shanghai Sho

GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)